Literature DB >> 8617791

Roles of active site residues and the NH2-terminal domain in the catalysis and substrate binding of human Cdc25.

X Xu1, S P Burke.   

Abstract

Human Cdc25 proteins are dual specific protein phosphatases that play important roles in cell cycle regulation. In this study, the catalytic mechanism and substrate binding specificity of human Cdc25A and -B proteins were investigated by site-directed and deletion mutagenesis methods. Mutations of the cysteine or the arginine residues in the active site motif abolished the Cdc25 phosphatase activity. However, the cysteine mutation in both Cdc25A and -B created enzymes that still retain the ability to bind their substrates. This allowed us to test the ability of Cdc25A and -B to bind various cyclin-Cdk complexes in vitro. While Cdc25A Cys --> Ser could interact with cyclin A-Cdk2, cyclin B-Cdc2, and cyclin E-Cdk2 strongly, Cdc25B mutant was only found to bind to cyclin A-Cdk2 at significant levels. We also identified Arg452 and Ser449 as two crucial residues that could be directly involved in the molecular interactions between Cdc25 and cyclin-Cdk proteins. Deletion mutagenesis data also indicate that the phosphatase catalytic domains of Cdc25A and -B proteins are located within their carboxyl terminus.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617791     DOI: 10.1074/jbc.271.9.5118

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  17 in total

1.  Cdc25B functions as a novel coactivator for the steroid receptors.

Authors:  Z Q Ma; Z Liu; E S Ngan; S Y Tsai
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

2.  Chk1, but not Chk2, inhibits Cdc25 phosphatases by a novel common mechanism.

Authors:  Katsuhiro Uto; Daigo Inoue; Ken Shimuta; Nobushige Nakajo; Noriyuki Sagata
Journal:  EMBO J       Date:  2004-07-22       Impact factor: 11.598

3.  Inappropriate activation of cyclin-dependent kinases by the phosphatase Cdc25b results in premature mitotic entry and triggers a p53-dependent checkpoint.

Authors:  Shohreh Varmeh; James J Manfredi
Journal:  J Biol Chem       Date:  2009-01-09       Impact factor: 5.157

4.  Ectopic expression of Cdc25A accelerates the G(1)/S transition and leads to premature activation of cyclin E- and cyclin A-dependent kinases.

Authors:  I Blomberg; I Hoffmann
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

5.  Adventitious arsenate reductase activity of the catalytic domain of the human Cdc25B and Cdc25C phosphatases.

Authors:  Hiranmoy Bhattacharjee; Ju Sheng; A Abdul Ajees; Rita Mukhopadhyay; Barry P Rosen
Journal:  Biochemistry       Date:  2010-02-02       Impact factor: 3.162

6.  A novel MAs(III)-selective ArsR transcriptional repressor.

Authors:  Jian Chen; Venkadesh Sarkarai Nadar; Barry P Rosen
Journal:  Mol Microbiol       Date:  2017-09-13       Impact factor: 3.501

7.  A small CDC25 dual-specificity tyrosine-phosphatase isoform in Arabidopsis thaliana.

Authors:  Isabelle Landrieu; Marco da Costa; Lieven De Veylder; Frédérique Dewitte; Klaas Vandepoele; Sahar Hassan; Jean-Michel Wieruszeski; Florence Corellou; Jean-Denis Faure; Marc Van Montagu; Dirk Inzé; Guy Lippens
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-25       Impact factor: 11.205

8.  Chk1 kinase negatively regulates mitotic function of Cdc25A phosphatase through 14-3-3 binding.

Authors:  Mei-Shya Chen; Christine E Ryan; Helen Piwnica-Worms
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

9.  The mammalian Cut homeodomain protein functions as a cell-cycle-dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase.

Authors:  O Coqueret; G Bérubé; A Nepveu
Journal:  EMBO J       Date:  1998-08-17       Impact factor: 11.598

10.  Ibp1p, a novel Cdc25-related phosphatase, suppresses Schizosaccharomyces pombe hsk1 ( cdc7).

Authors:  Hilary A Snaith; John Marlett; Susan L Forsburg
Journal:  Curr Genet       Date:  2003-07-09       Impact factor: 3.886

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.